GSK stock crumbled on Wednesday after vaccine sales tumbled, leading to a third-quarter miss. Revenue from RSV shot Arexvy ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

GSK said its depemokimab respiratory drug met the main objectives in two late-stage clinical trials, showing efficacy for the treatment of chronic rhinosinusitis with nasal polyps. The U.K ...

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

These products broadly target infectious diseases, HIV, respiratory and immunology, oncology, and other smaller "opportunity-driven" IPs. In my view, you can think of GSK as a company with a set ...

AI and clinical development with Cambridge’s complementary expertise GSK is investing more than £50 million in the CG-TIC to further accelerate research and development in kidney and respiratory ...

The virus generally causes outbreaks of respiratory tract disease from late fall to early spring, the agency’s RSV webpage ...

Shares of GSK fell over 3% following its third-quarter 2024 earnings, as investors reacted to underwhelming sales figures in ...